Study | Number of patients (BNP-guided/symptom-guided) | Age (years) Mean (SD) | Patients ≥ 75 years n (%) | Male n (%) | LVEF (%) Median (IQR)* | LVEF ≥ 40%**n (%) | NYHA class I/II/III/IV | Smoking status (non-smoker/ex-smoker/current smoker) | Body mass index, kg/m2(mean, SD) | Systolic BP, mmHG (mean, SD) | Diastolic BP, mmHG (mean, SD) |
---|---|---|---|---|---|---|---|---|---|---|---|
Studies that provided IPD | |||||||||||
Anguita [20] | 60 (30/30) | 69 (10) | 18/54 (33%) | 41/60 (68%) | 40 (26, 65) | 27/55 (49%) | 3/38/19/0 | 37/7/16 | – | – | – |
Northstar [27] | 407 (199/208) | 73 (8) | 186/407 (46%) | 309/407 (76%) | 30 (25, 35) | 36/402 (9%) | 80/268/59/0 | 47/114/110 | 26 (5) | 127 (19) | 73 (12) |
Shochat [32] | 120 (60/60) | 70 (11) | 50/120 (42%) | 103/120 (86%) | 30 (25, 35) | 11/75 (15%) | 1/55/41/16 | 34/0/40 | – | 125 (21) | 74 (11) |
Starbrite [31] | 130 (65/65) | 60 (15) | 24/130 (18%) | 91/130 (70%) | 20 (15, 25) | 0/129 (0%) | – | – | 29 (8) | 111 (21) | 69 (13) |
Upstep [24] | 268 (140/128) | 71 (10) | 105/268 (39%) | 196/268 (73%) | – | 0/268 (0%) | 0/83/147/37 | – | 27 (5) | – | – |
All | 985 (494/491) | 70 (11) | 383/979 (39%) | 740/985 (75%) | 30 (20, 35) | 74/929 (8%) | 84/444/266/53 | 118/121/166 | 27 (5) | 124 (21) | 73 (12) |
Studies that provided aggregate data§ | |||||||||||
Christchurch Pilot [29] | 69 (33/36) | 70 (10) | 24/69 (35%) | 53/69 (7%) | 27 (8) | 0/69 (0%) | ~ 70% (class II) | – | – | 127 (SD not provided) | 76 (SD not provided) |
Time-CHF HFrEF [26] | 499 (251/248) | 76 (8) | 289/499 (58%) | 327/499 (66%) | 30 (8) | 0/499 (0%) | 371/499 (74%) (≥ class III) | – | 25 (4) | 119 (19) | – |
Time-CHF HFpEF [33] | 123 (59/64) | 80 (7) | – | 42/123 (34%) | 56 (6) | 123/123 (100%) | 0/21/82/20 | – | 27 (5) | 136 (23) | 74 (12) |
Berger [21] | 188 (92/96) | 71 (12) | 88/188 (47%) | 147/188 (78%) | 29 (9) | 11/188 (6%) | All patients class III–IV | – | – | 121 (18) | 72 (12) |
Prima [22] | 345 (174/171) | 72 (12) | 166/345 (48%) | 197/345 (57%) | 36 (14) | 93/345 (27%) | 37/234/74 | 166/105/74 | – | 118 (21) | 69 (11) |
Signal-HF [25] | 252 (127/125) | 78 (7) | 184/252 (73%) | 180/252 (71%) | 32 (8) | 5/252 (2%) | 0/154/96/0 | – | – | 134 (22) | 74 (12) |
Battlescarred [28] | 242 (121/121) | 74 (9) | 138/242 (57%) | 157/242 (65%) | 39 (15) | 90/242 (37%) | 24/162/52/4 | – | – | 124 (23) | 71 (13) |
Stars-BNP [23] | 220 (110/110) | 66 (5) | – | 127/220 (58%) | 31 (8) | – | – | 101/220 (current smokers) | – | – | – |
Protect [30] | 151 (75/76) | 63 (14) | 38/151 (25%) | 127/151 (84%) | 27 (9) | 0/151 (0%) | 129/151 (85%) (class II–III) | 92/48/11 | 29 (6) | 110 (16) | 66 (9) |
Guide-IT [11] | 894 (446/448) | 62 (51 to 70) in BNP-guided group, 64 (54–72) in symptom-guided group*** | 161/894 (18%) | 608/894 (68%) | 25 (19 to 30)*** | All had LVEF ≤ 40% | 59/447/358/17 of 881 | – | – | 114 (102 to 128) in BNP-guided group, 114 (101 to 128) in symptom-guided group*** | – |